AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April.
from Reuters: Health News https://reut.rs/2Io3Hgz
http://bit.ly/2zwRqiM